Chemed (NYSE:CHE) Share Price Breaks Above 200-Day Moving Average – What’s Next?

Posted by Brian Himes on Oct 9th, 2026

Chemed Corporation (NYSE:CHE – Get Free Report)’s share price passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $465.26 and traded as high as $514.67. Chemed shares last traded at $500.4650, with a volume of 139,128 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CHE. Royal Bank Of Canada upped their price target on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research report on Thursday, July 30th. Oppenheimer boosted their price objective on Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Bank of America reissued a “neutral” rating on shares of Chemed in a report on Wednesday, July 29th. Weiss Ratings raised shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Finally, Wall Street Zen cut shares of Chemed from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 19th. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $554.60.

Read Our Latest Analysis on CHE

Chemed Stock Up 0.2%

The business has a 50-day moving average price of $521.96 and a two-hundred day moving average price of $466.11. The company has a quick ratio of 0.89, a current ratio of 0.91 and a debt-to-equity ratio of 0.17. The firm has a market cap of $6.52 billion, a PE ratio of 25.07, a price-to-earnings-growth ratio of 2.02 and a beta of 0.51.

Chemed (NYSE:CHE – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. The company had revenue of $673.25 million for the quarter, compared to the consensus estimate of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.27 EPS. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, equities research analysts expect that Chemed Corporation will post 23.55 EPS for the current year.

Chemed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 0.6%. This is a boost from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. Chemed’s dividend payout ratio (DPR) is currently 14.06%.

Insiders Place Their Bets

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the completion of the transaction, the chief executive officer owned 70,418 shares in the company, valued at approximately $37,991,215.18. The trade was a 2.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Spencer S. Lee sold 1,000 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $541.04, for a total value of $541,040.00. Following the completion of the sale, the executive vice president owned 13,912 shares in the company, valued at $7,526,948.48. This represents a 6.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 9,190 shares of company stock worth $4,833,160. 3.33% of the stock is owned by insiders.

Institutional Trading of Chemed

A number of institutional investors have recently added to or reduced their stakes in CHE. BlackRock Inc. bought a new position in shares of Chemed in the 2nd quarter worth about $691,290,000. Epoch Investment Partners Inc. grew its holdings in shares of Chemed by 4.9% in the 4th quarter. Epoch Investment Partners Inc. now owns 322,408 shares of the company’s stock worth $137,945,000 after acquiring an additional 15,133 shares during the last quarter. First Trust Advisors LP increased its stake in Chemed by 24.7% in the 1st quarter. First Trust Advisors LP now owns 236,392 shares of the company’s stock worth $89,295,000 after purchasing an additional 46,791 shares in the last quarter. Copeland Capital Management LLC raised its stake in Chemed by 7.6% during the 1st quarter. Copeland Capital Management LLC now owns 147,957 shares of the company’s stock valued at $55,889,000 after purchasing an additional 10,406 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Chemed by 7.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 107,215 shares of the company’s stock worth $40,481,000 after purchasing an additional 7,807 shares in the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.

About Chemed

(Get Free Report)

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.